Skip to main content

Table 2 Multivariate analysis of prognostic factors for the entire group

From: Impact of cumulative cisplatin dose in childhood nasopharyngeal carcinoma based on neoadjuvant chemotherapy response in the intensity-modulated radiotherapy era: a real-world study

Endpoint Variable HR 95% CI for HR P valuea
DFS CC-CCD (< 160 vs. ≥ 160 mg/m2) 0.26 0.10–0.65 0.004
T stage (T1–3 vs. T4) 2.66 1.07–6.62 0.036
EBV DNA (< 4000 vs. ≥ 4000 copy/mL) 3.35 1.11–10.16 0.032
Smoking history (no vs. yes) 2.53 0.72–8.92 0.148
DMFS CC-CCD (< 160 vs. ≥ 160 mg/m2) 0.28 0.10–0.81 0.018
T stage (T1–3 vs. T4) 2.34 1.03–5.62 0.041
EBV DNA (< 4000 vs. ≥ 4000 copy/mL) 3.27 1.02–9.60 0.046
Smoking history (no vs. yes) 3.50 0.97–12.64 0.056
OS T stage (T1–3 vs. T4) 2.94 1.01–4.27 0.046
EBV DNA (< 4000 vs. ≥ 4000 copy/mL) 3.72 0.83–16.67 0.057
  1. HR hazards ratio, 95% CI 95% confidence interval, CC-CCD cumulative cisplatin dose during concurrent chemoradiotherapy, EBV Epstein-Barr virus, DFS disease-free survival, DMFS distant metastasis-free survival, OS overall survival
  2. aP values were calculated using an adjusted Cox proportional hazards model